Risk of uterine cervical cancer in inflammatory bowel disease: a systematic review and meta-analysis

References

• Jung YS, Han M, Park S, et al. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study. J Crohns Colitis. 2017;11(8):954–962. doi: 10.1093/ecco-jcc/jjx040.
   PubMed Web of Science ®Google Scholar
• Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105(7):1480–1487. doi: 10.1038/ajg.2009.760.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss Inflammatory Bowel Disease Cohort. Am J Gastroenterol. 2011;106(1):110–119. doi: 10.1038/ajg.2010.343.
   PubMed Web of Science ®Google Scholar
• Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–258. doi: 10.1038/ajg.2016.537.
   PubMed Web of Science ®Google Scholar
• Goetgebuer RL, Kreijne JE, Aitken CA, et al. Increased risk of high-grade cervical neoplasia in women with inflammatory bowel disease: a case-controlled cohort study. J Crohns Colitis. 2021;15(9):1464–1473. doi: 10.1093/ecco-jcc/jjab036.
   PubMed Web of Science ®Google Scholar
• Goldacre MJ, Wotton CJ, Yeates D, et al. Cancer in patients with ulcerative colitis, Crohn’s disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol. 2008;20(4):297–304. doi: 10.1097/MEG.0b013e3282f2a5e2.
   PubMed Web of Science ®Google Scholar
• Jussila A, Virta LJ, Pukkala E, et al. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013;48(12):1405–1413. doi: 10.3109/00365521.2013.846402.
   PubMed Web of Science ®Google Scholar
• Rungoe C, Simonsen J, Riis L, et al. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. Clin Gastroenterol Hepatol. 2015;13(4):693–700.e1. doi: 10.1016/j.cgh.2014.07.036.
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015;21(5):1089–1097. doi: 10.1097/MIB.0000000000000338.
   PubMed Web of Science ®Google Scholar
• Mann S, Jess T, Allin K, et al. Risk of cervical cancer in inflammatory bowel disease: a meta-analysis of population-based studies. Clin Transl Gastroenterol. 2022;13(7):e00513. doi: 10.14309/ctg.0000000000000513.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. doi: 10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156(8):787–788. doi: 10.1001/jamasurg.2021.0522.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2022 [cited 2022 Jan 21]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Singh S, Nagpal SJS, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(2):210–218. doi: 10.1016/j.cgh.2013.04.033.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690–1691. doi: 10.1001/jama.280.19.1690.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Higgins JPT. Meta-regression in Stata. Stata J. 2008;8(4):493–519. doi: 10.1177/1536867X0800800403.
   Web of Science ®Google Scholar
• Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford: Blackwell Science; 2002.
   Google Scholar
• Breslow NE, Day NE, Heseltine E. Statistical methods in cancer research. Volume I: the analysis of case-control studies. Lyon, France: International Agency for Research on Cancer; 1980.
   Google Scholar
• Algaba A, Guerra I, Marín-Jiménez I, et al. Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohns Colitis. 2015;9(4):326–333. doi: 10.1093/ecco-jcc/jjv032.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population‐based study. Cancer. 2001;91(4):854–862. doi: 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z.
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67(7):2015–2020. doi: 10.1002/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Liu X, Ji J, et al. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. 2012;127(1):180–185. doi: 10.1016/j.ygyno.2012.07.100.
   PubMed Web of Science ®Google Scholar
• Hutfless S, Fireman B, Kane S, et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(5):598–605. doi: 10.1111/j.1365-2036.2008.03766.x.
   PubMed Web of Science ®Google Scholar
• Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004;19(3):287–293. doi: 10.1111/j.1365-2036.2004.01858.x.
   PubMed Web of Science ®Google Scholar
• Karlén P, Löfberg R, Broström O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999;94(4):1047–1052. doi: 10.1111/j.1572-0241.1999.01012.x.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ registry. Am J Gastroenterol. 2014;109(2):212–223. doi: 10.1038/ajg.2013.441.
   PubMed Web of Science ®Google Scholar
• Suk R, Sonawane K, Chiao E, et al. Association between HPV-related cancers and inflammatory bowel disease. J Clin Oncol. 2018;36(15 Suppl.):e13576. doi: 10.1200/JCO.2018.36.15_suppl.e13576.
   Google Scholar
• Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2(12):1088–1095. doi: 10.1016/s1542-3565(04)00543-9.
   PubMed Web of Science ®Google Scholar
• Algaba A, Guerra I, Castaño Á, et al. Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease. World J Gastroenterol. 2013;19(48):9359–9365. doi: 10.3748/wjg.v19.i48.9359.
   PubMed Web of Science ®Google Scholar
• Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer. 1985;56(12):2914–2921. doi: 10.1002/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J.
   PubMed Web of Science ®Google Scholar
• Kvist N, Jacobsen O, Norgaard P, et al. Malignancy in Crohn’s ­disease. Scand J Gastroenterol. 1986;21(1):82–86. doi: 10.3109/00365528609034627.
   PubMed Web of Science ®Google Scholar
• Li M, Yang QF, Cao Q, et al. High-risk human papilloma virus infection and cervical neoplasm in female inflammatory bowel disease patients: a cross-sectional study. Gastroenterol Rep. 2019;7(5):338–344. doi: 10.1093/gastro/goy053.
   Google Scholar
• Mir‐Madjlessi SH, Farmer RG, Easley KA, et al. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer. 1986;58(7):1569–1574. doi: 10.1002/1097-0142(19861001)58:7<1569::AID-CNCR2820580731>3.0.CO;2-U.
   PubMed Web of Science ®Google Scholar
• Patel U, Lichtenstein G, Scott F. Malignancy outcomes in inflammatory bowel disease patients on immune modulators and anti-tumor necrosis factor therapy. Am J Gastroenterol. 2014;109:S484. doi: 10.14309/00000434-201410002-01633.
   PubMed Web of Science ®Google Scholar
• Persson P-G, Karlén P, Bernell O, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology. 1994;107(6):1675–1679. doi: 10.1016/0016-5085(94)90807-9.
   PubMed Web of Science ®Google Scholar
• Petrea OC, Stanciu C, Girleanu I, et al. Malignancies in patients with inflammatory bowel disease: a single-centre experience. Turk J Gastroenterol. 2019;30:S425–S426.
   Google Scholar
• Yu KH, Kuo CF, Huang LH, et al. Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases a nationwide population-based dynamic cohort study in Taiwan. Medicine. 2016;95(18):e3540. doi: 10.1097/MD.0000000000003540.
   PubMed Web of Science ®Google Scholar
• Dugué PA, Rebolj M, Hallas J, et al. Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: population-based cohort study. Int J Cancer. 2015;136(6):E711–E719. doi: 10.1002/ijc.29209.
   PubMed Web of Science ®Google Scholar
• Jess T, Horváth-Puhó E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108(12):1869–1876. doi: 10.1038/ajg.2013.249.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265–273.e1. doi: 10.1016/j.cgh.2013.03.034.
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Johansen C, Gridley G, et al. Crohn’s disease and cancer risk (Denmark). Cancer Causes Control. 2000;11(2):145–150. doi: 10.1023/a:1008988215904.
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Olsen JH, Frisch M, et al. Cancer in patients with ulcerative colitis. Int J Cancer. 1995;60(3):330–333. doi: 10.1002/ijc.2910600309.
   PubMed Web of Science ®Google Scholar
• Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015;74(7):1360–1367. doi: 10.1136/annrheumdis-2013-204993.
   PubMed Web of Science ®Google Scholar
• Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007;102(9):2058–2069. doi: 10.1111/j.1572-0241.2007.01343.x.
   PubMed Web of Science ®Google Scholar
• Kim H, Kim JH, Lee JK, et al. Incident Crohn’s disease as a risk factor for colorectal cancer in the first 10 years after diagnosis: a nationwide population-based study. J Clin Med. 2021;10(20):4663. doi: 10.3390/jcm10204663.
   PubMed Web of Science ®Google Scholar
• Kim HM, Kim JH, Lee JK, et al. Age- and sex-specific risk of colorectal cancer in incident ulcerative colitis during the first 10 years after diagnosis: a nationwide population-based study. Scand J Gastroenterol. 2021;56(11):1279–1285. doi: 10.1080/00365521.2021.1958370.
   PubMed Web of Science ®Google Scholar
• Lo B, Zhao M, Vind I, et al. The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2021;19(6):1117–1138.e19. doi: 10.1016/j.cgh.2020.08.015.
   PubMed Web of Science ®Google Scholar
• Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197–e206. doi: 10.1016/S2214-109X(22)00501-0.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11(13):4717–4723. doi: 10.1158/1078-0432.CCR-04-2599.
   PubMed Web of Science ®Google Scholar
• McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425–434. doi: 10.1016/S1470-2045(08)70103-7.
   PubMed Web of Science ®Google Scholar
• Ng SC. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol. 2014;28(3):363–372. doi: 10.1016/j.bpg.2014.04.003.
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol. 2014;20(33):11525–11537. doi: 10.3748/wjg.v20.i33.11525.
   PubMed Web of Science ®Google Scholar
• Andersen NN, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–2413. doi: 10.1001/jama.2014.5613.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385–1397.e10. doi: 10.1016/j.cgh.2016.04.039.
   PubMed Web of Science ®Google Scholar
• Muller M, D’Amico F, Bonovas S, et al. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis. 2021;15(5):840–859. doi: 10.1093/ecco-jcc/jjaa186.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–1348. doi: 10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar
• De Sanjose S, Wheeler CM, Quint WG, et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(7):1313–1318. doi: 10.1158/1055-9965.EPI-13-0053.
   PubMed Web of Science ®Google Scholar
• Chelimo C, Wouldes TA, Cameron LD, et al. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect. 2013;66(3):207–217. doi: 10.1016/j.jinf.2012.10.024.
   PubMed Web of Science ®Google Scholar